Search
ISSN:
0091-2700
eISSN:
1552-4604
Disciplines
(Field of Science):
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
(Field of Science)
Ministry points: Help
| Year | Points | List |
|---|---|---|
| Year 2024 | 100 | Ministry scored journals list 2024 |
| Year | Points | List |
|---|---|---|
| 2024 | 100 | Ministry scored journals list 2024 |
| 2023 | 100 | Ministry Scored Journals List |
| 2022 | 100 | Ministry Scored Journals List 2019-2022 |
| 2021 | 100 | Ministry Scored Journals List 2019-2022 |
| 2020 | 100 | Ministry Scored Journals List 2019-2022 |
| 2019 | 100 | Ministry Scored Journals List 2019-2022 |
| 2018 | 30 | A |
| 2017 | 30 | A |
| 2016 | 25 | A |
| 2015 | 25 | A |
| 2014 | 30 | A |
| 2013 | 30 | A |
| 2012 | 35 | A |
| 2011 | 35 | A |
| 2010 | 27 | A |
Model:
Hybrid
Points CiteScore:
| Year | Points |
|---|---|
| Year 2023 | 5.1 |
| Year | Points |
|---|---|
| 2023 | 5.1 |
| 2022 | 5.3 |
| 2021 | 5 |
| 2020 | 4.8 |
| 2019 | 5.2 |
| 2018 | 5.4 |
| 2017 | 5.4 |
| 2016 | 5.2 |
| 2015 | 5.5 |
| 2014 | 5.4 |
| 2013 | 5.5 |
| 2012 | 5.4 |
| 2011 | 6.3 |
Impact Factor:
Log in to see the Impact Factor.
Sherpa Romeo:
Papers published in journal
Filters
total: 9
Catalog Journals
Year 2020
-
Population Pharmacokinetic Model of Dexmedetomidine in a Heterogeneous Group of Patients
Publication
Year 2017
-
Flip-Flop Phenomenon in Epidural Sufentanil Pharmacokinetics: A Population Study in Children and Infants
Publication
Year 2016
-
Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia
Publication -
Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients
Publication
Year 2015
Year 2014
-
Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease
Publication
Year 2010
-
Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes
Publication -
Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus
Publication -
Population Modeling of Filgrastim PK-PD in Healthy Adults Following Intravenous and Subcutaneous Administrations
Publication
seen 374 times